Saudi Alyoom

A Danish official fainted on air during a press conference about vaccinations

98

The director of the pharmacovigilance department at the Danish Medicines Agency, Tania Eriks, passed out on Wednesday during a press conference about vaccinations.

Social media users circulated a video clip showing the Danish official falling to the ground at the time, when preparations were being made for a press conference about vaccinations in the country.

The agency said on Twitter, “She woke up again, she is fine, but was sent by ambulance to the emergency room for examination by doctors.”

The agency did not mention the causes of the accident, but confirmed that assistance was provided to Eriks, and the press conference will soon resume.

The Danish Health Authority confirmed in a statement issued yesterday that the country will continue its vaccination campaign against the coronavirus without using the “AstraZeneca” vaccine, noting that this decision was issued by the National Health Care Committee against the background of discovering a link between this drug and the clots that appeared in the blood of a number of people. They underwent vaccination with it.

The head of the council, Soren Bröström, indicated that the tests discovered the presence of a “rare but dangerous side effect” of the “AstraZeneca” vaccine, pointing out at the same time that the new decision does not require the withdrawal of the license granted in the country for this vaccine.

The official explained that he shares the European Medicines Agency’s position that the benefits of the “AstraZeneca” vaccine significantly exceed the seriousness of the aforementioned strokes, and said that he would have ordered the use of this drug if Denmark faced a new wave of coronavirus with the increasing pressures on the health care system.

The Danish channel TV2 stated that this measure will lead to the delay of the Corona vaccination campaign in the country for some weeks.

On March 11, the Danish authorities decided to temporarily suspend the use of the “AstraZeneca” vaccine, and extended this decision on March 25 for a period of three weeks.

Comments are closed.